US12351553B2 - Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation - Google Patents
Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation Download PDFInfo
- Publication number
- US12351553B2 US12351553B2 US17/961,978 US202217961978A US12351553B2 US 12351553 B2 US12351553 B2 US 12351553B2 US 202217961978 A US202217961978 A US 202217961978A US 12351553 B2 US12351553 B2 US 12351553B2
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- mixture
- group
- compound
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a production method of a pyrrole compound useful as a pharmaceutical product, particularly an acid secretion inhibitor, a production method of an intermediate used for this method, a novel intermediate and the like.
- a pyrrole compound having a substituted sulfonyl group at the 1-position (hereinafter to be referred to as a sulfonylpyrrole compound) is useful as an acid secretion inhibitor (proton pump inhibitor), a therapeutic drug for a neoplastic disease or an autoimmune disease (patent documents 1-3).
- Patent document 11 describes 2-mercaptopyrrole derivative (C) having a cyano group at the 3-position:
- non-patent document 5 describes, as shown in the following reaction scheme, a synthesis method of mercaptopyrrole derivative (A) by a reaction of a (2-oxoethyl)malononitrile derivative with hydrogen sulfide; however, a desulfurization reaction is not described.
- non-patent document 6 describes, as shown in the following reaction scheme, a synthesis method of 2-mercaptopyrrole derivative (B) having a cyano group at the 3-position is described; however, it is not by a ring closure reaction of a (2-oxoethyl)malononitrile derivative and a sulfur compound. Furthermore, a desulfurization reaction of the obtained 2-mercaptopyrrole derivative is not described.
- patent document 11 describes, as shown in the following reaction scheme, a synthesis method of 2-mercaptopyrrole derivative (C) having a cyano group at the 3-position; however, it is not by a ring closure reaction of a (2-oxoethyl)malononitrile derivative and a sulfur compound. Furthermore, a desulfurization reaction of the obtained 2-mercaptopyrrole derivative is not described.
- patent document 12 describes, as shown in the following reaction scheme, a synthesis method of 2-mercaptopyrrole derivative (D) having a cyano group at the 3-position; however, it is not by a ring closure reaction of a (2-oxoethyl)malononitrile derivative and a sulfur compound. In addition, a desulfurization reaction of the obtained 2-mercaptopyrrole derivative is not described.
- a more efficient production method of a sulfonylpyrrole compound useful as a pharmaceutical product is desired.
- provision of an intermediate used for this method is desired.
- the present inventors have intensively studied a production method of a sulfonylpyrrole compound useful as an acid secretion inhibitor, particularly a compound represented by the formula (VIII):
- the present invention relates to the following invention.
- R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- R 2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom
- R 3 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- R 4 is an alkyl group, or a salt thereof, comprising (I) reducing a compound represented by the formula
- R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- R 2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising subjecting a compound represented by the formula
- R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- R 2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising reducing a compound represented by the formula
- R 5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group or a group represented by —S—R 6 (R 6 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), and n is 0, 1 or 2, or a salt thereof, to a desulfurization reaction; (7) a method of producing a compound represented by the formula
- R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- R 2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising reacting a compound represented by the formula
- 3-cyanopyrrole compound a (2-oxoethyl)malononitrile compound is reacted with a sulfur compound to give a 2-mercapto-3-cyanopyrrole compound, which is then subjected to a desulfurization reaction to give the object compound in a high yield.
- 2-mercapto-3-cyanopyrrole can be used as a novel intermediate for a 3-cyanopyrrole compound.
- the present invention relates to a production method of a sulfonylpyrrole compound useful as an acid secretion inhibitor, particularly, a compound represented by the formula (VIII):
- halogen atom for X 1 examples include chlorine, bromine and the like.
- hydrocarbon group of the “optionally substituted hydrocarbon group” for R 1 examples include a chain or cyclic hydrocarbon group (e.g., alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl etc.). Of these, a chain or cyclic hydrocarbon group having a carbon number of 1 to 16 and the like are preferable.
- alkyl examples include C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) and the like.
- alkenyl examples include C 2-6 alkenyl (e.g., vinyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl etc.) and the like.
- aryl examples include C 6-14 aryl (e.g., phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.) and the like.
- aralkyl examples include C 7-16 aralkyl (e.g., phenyl-C 1-6 alkyl such as benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl and the like, naphthyl-C 1-6 alkyl, diphenyl-C 1-4 alkyl etc.) and the like.
- phenyl-C 1-6 alkyl such as benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl and the like, naphthyl-C 1-6 alkyl, diphenyl-C 1-4 al
- heterocyclic group of the “optionally substituted heterocyclic group” for R 1 examples include a 3- to 8-membered heterocyclic group (preferably a 5- or 6-membered heterocyclic group) containing 1 to 4 hetero atoms such as a nitrogen atom (optionally oxidized), an oxygen atom, a sulfur atom (optionally mono- or dioxidized) and the like, or a 3- to 8-membered heterocyclic group (preferably a 5- or 6-membered heterocyclic group) containing 1 to 4 hetero atoms such as a nitrogen atom (optionally oxidized), an oxygen atom, a sulfur atom (optionally mono- or dioxidized) and the like, with a benzene ring; or a group formed by condensing a 3- to 8-membered heterocyclic group (preferably 5- or 6-membered heterocyclic group) containing 1 to 4 hetero atoms such as a nitrogen atom (optionally oxidized), an oxygen atom, a sulfur atom (optionally
- aziridinyl e.g., 1- or 2-aziridinyl
- azirinyl e.g., 1- or 2-azirinyl
- azetyl e.g., 2-, 3- or 4-azetyl
- azetidinyl e.g., 1-, 2- or 3-azetidinyl
- perhydroazepinyl e.g., 1-, 2-, 3- or 4-perhydroazepinyl
- perhydroazocinyl e.g., 1-, 2-, 3-, 4- or 5-perhydroazocinyl
- pyrrolyl e.g., 1-, 2- or 3-pyrrolyl
- pyrazolyl e.g., 1-, 3-, 4- or 5-pyrazolyl
- imidazolyl e.g., 1-, 2-, 4- or 5-imidazolyl
- triazolyl e.g., 1,2,3-triazole-1-, 4- or 5-
- Examples of the “substituent” of the heterocyclic group include those similar to the substituents optionally present when the “hydrocarbon group” for the above-mentioned R 1 is cycloalkyl, aryl or aralkyl.
- the number of the substituents is 1 to 5, preferably 1 to 3.
- alkyl group of the “optionally substituted alkyl group” for R 2 examples include C 1-6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like, and the like.
- the “alkyl group” optionally has, (1) a halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (2) nitro, (3) cyano, (4) hydroxy, (5) C 1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, fluoromethoxy etc.) optionally having 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), (6) C 6-14 aryloxy (e.g., phenyloxy, naphthyloxy etc.), (7) C 7-16 aralkyloxy (e.g., benzyloxy, phenethyloxy, diphenylmethyloxy, 1-naphthylmethyloxy, 2-naphthylmethyl
- the number of the substituents is 1 to 3.
- acyl group an acyl group having 1 to 20 carbon atoms, which is derived from organic carboxylic acid can be mentioned.
- C 1-7 alkanoyl groups e.g., formyl; C 1-6 alkyl-carbonyl such as acetyl, propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl, heptanoyl and the like; etc.
- C 6-14 aryl-carbonyl groups e.g., benzoyl, naphthalenecarbonyl etc.
- C 1-6 alkoxy-carbonyl groups e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl etc.
- C 6-14 aryloxy-carbonyl groups e.g.
- acyl group is an aryl-carbonyl group, an aryloxy-carbonyl group, an aralkyl-carbonyl group, an aralkyloxycarbonyl group, a 5- or 6-membered heterocyclyl-carbonyl group or a 5- or 6-membered heterocyclyl-acetyl group, it is optionally substituted by 1 to 5 (preferably 1 to 3) alkyl groups (e.g., C 1-6 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and the like, C 3-6 cycloalkyl such as cyclohexyl and the like, and the like), alkenyl
- Examples of the “optionally substituted heterocyclic group” for R 8 include groups similar to the “optionally substituted heterocyclic group” for the aforementioned R 1 .
- a C 6-14 aryl group e.g., phenyl group
- substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C 1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexy
- R 1 [1] a C 6-14 aryl group (e.g., phenyl group) optionally substituted by 1 to 5 (preferably 1 to 3) substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C 1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy,
- substituents selected
- a thienyl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C 1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.
- a phenyl group optionally substituted by 1 to 5 (preferably 1 to 3) substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine),
- a halogen atom e.g., fluorine, chlorine, bromine, iodine
- C 1-6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl
- a thienyl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), or [3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) lower (specifically C 1-6 ) alkyl (e.g., methyl, ethyl
- R 4 methyl or ethyl is preferable, and methyl is particularly preferable.
- R 3 is a 5- or 6-membered aromatic nitrogen-containing monocyclic heterocyclic group (e.g., thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and the like) or an imidazo[1,2-a]pyrimidinyl group, which are optionally substituted by 1 to 3 substituents selected from (i) halogen (e.g., fluorine, chlorine, bromine, iodine), (ii) hydroxy, (iii) cyano, (iv) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., thiazoly
- a thienyl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) C 1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), or [3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) lower (specifically C 1-6 ) alkyl (e.g., methyl, ethyl
- halogen atom for X 1 chlorine or bromine is preferable, and chlorine is more preferable.
- a halogen atom such as chlorine, bromine or the like or a hydroxy group is preferable, and a halogen atom is more preferable.
- an optionally substituted C 1-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.
- C 1-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.
- an optionally substituted C 1-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl etc.
- C 1-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl etc.
- compound (VIII) which is an object compound, include 1- ⁇ 5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl ⁇ -N-methylmethanamine or a salt thereof, 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof, N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine or a salt thereof, 1-[5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof, 1-[5-(2-fluoropyridin-3-yl)-1-(
- the salt with organic base include a salt with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine and the like.
- the salt with inorganic acid include a salt with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- Compound (II) or a salt thereof can be produced by cyclizing compound (I) or a salt thereof in the presence of hydrogen halide.
- the dehalogenation is preferably performed in the presence of a base.
- a base for example, inorganic bases such as sodium hydride, sodium hydroxide, potassium hydroxide and the like, basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate and the like, metal bases such as potassium ethoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide and the like, aromatic amines such as pyridine, lutidine and the like, tertiary amines such as diisopropylethylamine, triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-N,N-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like, and the like can be mentioned.
- the dehalogenation is generally performed in a solvent inert to the reaction.
- solvent include alcohols (e.g., methanol, ethanol, propanol, butanol and the like), hydrocarbons (e.g., benzene, toluene, xylene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), carboxylic acids (e.g., acetic acid and the like), water and a mixture thereof.
- the amount of the solvent to be used is generally about 1 to about 100 ml, preferably about 1 to about 50 ml, per 1 g of
- the hydrogen pressure under which the reaction is performed is generally about 0 to about 10 atm, preferably about 0 to about 5 atm.
- the reaction temperature is generally about ⁇ 50° C. to about 100° C., preferably about ⁇ 20° C. to about 50° C.
- the reaction time is generally about 0.5 to about 24 hr, preferably about 0.5 to about 10 hr.
- Compound (IV) or a salt thereof can be produced by reducing compound (III) or a salt thereof and hydrolyzing the reduced product.
- the metal hydride examples include boron reagent (e.g., sodium borohydride, lithium borohydride, zinc borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, lithium cyanoborohydride and the like), aluminum reagent (e.g., diisobutylaluminum hydride, aluminum hydride, lithium aluminum hydride and the like), borane complex (e.g., borane-THF complex, borane-dimethylsulfide, borane-pyridine and the like), catechol borane and the like.
- the amount of the metal hydride to be used is, for example, about 0.2 to about 10 mol, preferably about 0.2 to about 5 mol, per 1 mol of compound (III).
- the reduction reaction by metal hydride is generally performed in a solvent inert to the reaction.
- solvent include aromatic hydrocarbons (e.g., toluene, xylene, chlorobenzene and the like), aliphatic hydrocarbons (e.g., heptane, hexane and the like), halogenated hydrocarbons (e.g., chloroform, dichloromethane and the like), ethers (e.g., diethyl ether, tetrahydrofuran, dioxane and the like), and a mixture thereof.
- the amount of the solvent to be used is generally about 1 to about 100 ml, preferably about 1 to about 50 ml, per 1 g of compound (III).
- the reaction temperature is generally about ⁇ 100° C. to about 100° C., preferably about ⁇ 70° C. to about 50° C.
- the reaction time is generally about 0.5 to about 24 hr, preferably about 0.5 hr to about 5 hr.
- the catalytic hydrogenation can be performed in the presence of a hydrogen source and a metal catalyst.
- the metal catalyst include palladium catalyst (e.g., palladium carbon, palladium hydroxide carbon, palladium oxide and the like), nickel catalyst (e.g., Raney-nickel and the like), platinum catalyst (e.g., platinum oxide, platinum carbon and the like), rhodium catalyst (e.g., rhodium carbon and the like) and the like. Of these, palladium carbon or Raney-nickel is preferable.
- the amount of the metal catalyst to be used is about 0.0001 to about 10 mol, preferably about 0.001 to about 5 mol, per 1 mol of compound (III), or about 0.1 g to about 10 g, preferably about 0.3 g to about 5 g, per 1 g of compound (III).
- Examples of the hydrogen source include hydrogen gas, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like.
- a hydrogen source other than hydrogen gas a compound of a hydrogen source is used in about 1 to about 100 mol, preferably about 1 to about 50 mol, more preferably about 1 to about 10 mol, for example, about 1 to about 5 mol, per 1 mol of compound (III).
- the catalytic hydrogenation is generally performed in a solvent inert to the reaction.
- solvent include alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), carboxylic acids (e.g., acetic acid and the like), water and a mixture thereof.
- the amount of the solvent to be used is generally about 1 to about 1000 ml, preferably about 1 to about 100
- the hydrogen pressure under which the reaction is performed is generally about 0 to about 10 atm, preferably about 0 to about 5 atm.
- the reaction temperature is generally about ⁇ 50° C. to about 100° C., preferably about ⁇ 20° C. to about 50° C.
- the reaction time is generally about 1 to about 100 hr, preferably about 1 to about 24 hr, for example, about 1 to about 10 hr.
- the hydrolysis can be performed in the presence of an acid or a base.
- the acid include inorganic acid (hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, boric acid and the like), organic carboxylic acid (formic acid, acetic acid, propionic acid and the like), organic sulfonic acid (methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid and the like) and the like.
- the amount of the acid to be used is about 0.1 to about 10 mol, preferably about 0.1 to about 5 mol, per 1 mol of compound (III).
- the base examples include inorganic bases such as sodium hydroxide, potassium hydroxide and the like, basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate etc., and the like.
- the amount of the base to be used is about 0.1 to about 10 mol, preferably about 0.1 to about 5 mol, per 1 mol of compound (III).
- the hydrolysis is advantageously performed using a solvent inert to the reaction.
- solvent is not particularly limited as long as the reaction proceeds, alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), carboxylic acids (e.g., acetic acid and the like), water and a mixture thereof can be mentioned.
- the amount of the solvent to be used is generally about 1 to about 100 ml, preferably about 1 to about 50 ml, per 1 g of compound
- the reaction temperature is generally about ⁇ 20° C. to about 100° C., preferably about 0° C. to about 50° C.
- the reaction time is generally about 1 to about 48 hr, preferably about 1 to about 24 hr.
- Compound (VI) or a salt thereof can be produced by subjecting compound (IV) or a salt thereof to a reaction with compound (V) or a salt thereof.
- the amount of compound (V) to be used is preferably about 1 to about 10 mol, more preferably about 1 to about 5 mol, per 1 mol of compound (IV).
- This reaction is advantageously performed using a solvent inert to the reaction.
- solvent is not particularly limited as long as the reaction proceeds, alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), acid nitriles (e.g., acetonitrile, propionitrile and the like), water and a mixture thereof can be mentioned.
- the amount of the solvent to be used
- This reaction is preferably performed in the presence of a base.
- the base include inorganic bases such as sodium hydride, sodium hydroxide, potassium hydroxide and the like, basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate and the like, metal bases such as potassium ethoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide and the like, aromatic amines such as pyridine, lutidine and the like, tertiary amines such as diisopropylethylamine, triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-N,N-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like, and a mixture thereof and the like.
- the amount of the base to be used is about 0.01 to about 10 mol,
- the reaction can also be carried out in the co-presence of crown ether.
- the crown ether for example, 15-crown-5-ether, 18-crown-6-ether and the like can be mentioned.
- the amount of the crown ether to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (IV).
- the reaction time is generally about 30 min to about 24 hr, preferably about 30 min to about 8 hr.
- the reaction temperature is generally about 0° C. to about 100° C., preferably about 10° C. to about 50° C.
- Compound (VIII) or a salt thereof can be produced by reacting compound (VI) or a salt thereof with compound (VII) or a salt thereof, and reducing the imine formed.
- compound (VIII) or a salt thereof can be produced without isolating the imine formed by performing the reaction of compound (VI) or a salt thereof with compound (VII) or a salt thereof in the presence of a reducing agent.
- This reaction can be performed according to the conventional reaction conditions known as reductive amination reaction.
- the reaction can be performed according to the method described in Jikken Kagaku Koza (Courses in Experimental Chemistry), vol. 14-III, pages 1380-1385 (Maruzen Co., Ltd.).
- This reaction is advantageously carried out using a solvent inert to the reaction.
- the solvent is not particularly limited as long as the reaction proceeds, and alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), water and a mixture thereof can be mentioned.
- the amount of the solvent to be used is generally 1 to 100 ml, preferably 1 to 50 ml, per 1 g of compound
- sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride and the like can be used as a reducing agent.
- the amount of the reducing agent to be used is preferably about 0.2 to about 10 mol, more preferably about 0.2 to about 5 mol, per 1 mol of compound (VI).
- the reduction can also be performed by catalytic hydrogenation.
- the catalytic hydrogenation can be performed in the presence of a hydrogen source and a metal catalyst.
- the metal catalyst include palladium catalyst (e.g., palladium carbon, palladium hydroxide carbon, palladium oxide and the like), nickel catalyst (e.g., Raney-nickel and the like), platinum catalyst (e.g., platinum oxide, platinum carbon and the like), rhodium catalyst (e.g., rhodium carbon and the like), cobalt catalyst (e.g., Raney-cobalt and the like) and the like.
- palladium carbon or Raney-nickel is preferable.
- the amount of the metal catalyst to be used is about 0.01 to about 10 mol, preferably about 0.01 to about 5 mol, per 1 mol of compound (VI).
- a hydrogen source hydrogen gas, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned.
- a hydrogen source other than hydrogen gas a compound of a hydrogen source is used in about 1 to about 100 mol, preferably about 1 to about 50 mol, more preferably about 1 to about 10 mol, for example, about 1 to about 5 mol, per 1 mol of compound (VI).
- the reduction is advantageously performed using a solvent inert to the reaction.
- solvent is not particularly limited as long as the reaction proceeds, and alcohols (e.g., methanol, ethanol, propanol, butanol and the like), hydrocarbons (e.g., benzene, toluene, xylene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), water and a mixture thereof can be mentioned.
- the amount of the solvent to be used is generally 1 to 100 ml, preferably 1 to 50 ml, per 1 g of compound (VI).
- the reaction time is generally about 0.5 to about 24 hr, preferably about 0.5 to about 10 hr.
- the reaction temperature is generally about ⁇ 50° C. to about 100° C., preferably about ⁇ 20° C. to about 50° C.
- Compound (X) or a salt thereof can be produced by reacting compound (I) or a salt thereof with compound (IX) or a salt thereof.
- compound (IX) or a salt thereof thiocarboxylic acid (e.g., thiobenzoic acid), sodium thiomethoxide, a thiol compound represented by R 5 SH (R 5 is as defined above) and the like can be used.
- the amount of compound (IX) to be used is preferably about 1 to about 10 mol, more preferably about 1 to about 5 mol, per 1 mol of compound (I).
- Compound (III) or a salt thereof can be produced by subjecting compound (X) or a salt thereof to a desulfurization reaction.
- the desulfurization reaction using Raney-nickel is preferably performed in the presence of a base.
- a base secondary amine such as morpholine and the like can be mentioned.
- the amount of the base to be used is about 0.1 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (X).
- Compound (XVII) or a salt thereof can be produced by reacting compound (III) or a salt thereof with compound (V) or a salt thereof, as in step 4.
- Compound (VI) or a salt thereof can be produced by reducing compound (XVII) or a salt thereof, followed by hydrolysis, as in step 3.
- Compound (XI) or a salt thereof can be produced by reacting compound (I) or a salt thereof with a sulfur reagent.
- sulfur reagent examples include hydrogen sulfide, thioacetic acid, thiouric acid, thioacetamide and the like.
- the amount of the sulfur reagent to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (I).
- tertiary amines such as triethylamine, diisopropylethylamine and the like.
- the amount of the base to be used is about 0.1 to about 10 mol, preferably about 0.1 to about 5 mol, per 1 mol of compound (I).
- the reaction time is generally about 1 to about 50 hr, preferably about 1 to about 20 hr.
- the reaction temperature is generally about 0° C. to about 150° C., preferably about 0° C. to about 100° C.
- the desulfurization reaction can be performed by a method similar to Method 2, step 7.
- Compound (XIII) or a salt thereof can be produced by subjecting compound (XII) or a salt thereof to a reduction reaction.
- the reduction reaction can be performed by a catalytic hydrogenation and the like.
- the catalytic hydrogenation can be performed in the presence of a hydrogen source and a metal catalyst.
- the metal catalyst include palladium catalyst (e.g., palladium carbon, palladium hydroxide carbon, palladium oxide, palladium supported by carrier such as ceramic, cellulose, resin and the like, and the like), nickel catalyst (e.g., Raney-nickel and the like), platinum catalyst (e.g., platinum oxide, platinum carbon and the like), rhodium catalyst (e.g., rhodium carbon and the like), cobalt catalyst (Raney-cobalt and the like) and the like.
- palladium carbon or Raney-nickel is preferable.
- the amount of the metal catalyst to be used is about 0.001 to about 10 mol, preferably about 0.01 to about 5 mol, per 1 mol of compound (XII).
- hydrogen gas hydrogen gas, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned.
- a hydrogen source other than hydrogen gas a compound of a hydrogen source is used in about 0.1 to about 100 mol, preferably about 0.1 to about 50 mol, more preferably about 1 to about 50 mol, particularly preferably about 1 to about 5 mol, per 1 mol of compound (XII).
- the catalytic hydrogenation is generally performed in a solvent inert to the reaction.
- solvent include alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), carboxylic acids (e.g., acetic acid and the like), water and a mixture thereof.
- the amount of the solvent to be used is generally about 1 to about 1000 ml, preferably about 3 to about 100
- Compound (XII) or a salt thereof can be produced according to the method described in, for example, JP-A-6-9554 and the like, or a method analogous thereto.
- the cyclization reaction is preferably performed under acidic conditions.
- organic carboxylic acid formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid and the like
- organic sulfonic acid methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid and the like
- inorganic acid hydroochloric acid, sulfuric acid, nitric acid and the like
- the amount of the acid to be used is about 0.01 to about 100 mol, preferably about 0.1 to about 50 mol, per 1 mol of compound (XIII).
- This reaction is advantageously performed using a solvent inert to the reaction.
- solvent is not particularly limited as long as the reaction proceeds, and alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), carboxylic acids (e.g., acetic acid and the like), water and a mixture thereof can be mentioned.
- the amount of the solvent to be used is generally about 1 to about 1000
- the reaction time is generally about 0.1 to about 48 hr, preferably about 0.5 to about 6 hr.
- the reaction temperature is generally about ⁇ 10° C. to about 100° C., preferably about 25° C. to about 60° C.
- Compound (XIV) or a salt thereof can also be obtained by subjecting compound (XIII) or a salt thereof obtained in the aforementioned step 10, without isolation, to a cyclization reaction in the next step 11.
- the catalyst is filtered off from the reaction mixture obtained in step 10, the filtrate is concentrated as necessary, and an acid is added to cause reaction, whereby compound (XIV) or a salt thereof can be obtained.
- the kind and amount of the reaction solvents and reagents, reaction time and reaction temperature are similar to those in step 10 and step 11.
- Compound (VIII) or a salt thereof can be produced from compound (XIV) or a salt thereof by the aforementioned method of converting compound (III) to compound (VIII) or a method known per se.
- hydrogen gas As a hydrogen source, hydrogen gas, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like can be mentioned.
- a hydrogen source other than hydrogen gas a compound of a hydrogen source is used in about 1 to about 1000 mol, preferably about 3 to about 30 mol, per 1 mol of compound (XV).
- This reaction is advantageously performed using a solvent inert to the reaction.
- solvent is not particularly limited as long as the reaction proceeds, and alcohols (e.g., methanol, ethanol, propanol, butanol and the like), aromatic hydrocarbons (e.g., benzene, toluene, xylene, chlorobenzene and the like), halogenated hydrocarbons (e.g., dichloromethane, chloroform and the like), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran and the like), esters (e.g., ethyl acetate and the like), amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide and the like), carboxylic acids (e.g., acetic acid and the like), water and a mixture thereof can be mentioned.
- the amount of the solvent to be used is generally about 1 to about 1000
- the cyclization reaction is preferably performed in the presence of an acid.
- the acid include organic carboxylic acid (formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid and the like), organic sulfonic acid (methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid and the like), inorganic acid (hydrochloric acid, sulfuric acid, nitric acid and the like) and the like.
- the amount of the acid to be used is about 0.01 to about 100 mol, preferably about 0.1 to about 50 mol, per 1 mol of compound (XV).
- the reaction time is generally about 0.5 to about 48 hr, preferably about 1 to about 12 hr.
- the reaction temperature is generally about ⁇ 10° C. to about 100° C., preferably about 10° C. to about 50° C.
- Compound (VIII) or a salt thereof can be produced from compound (XVI) or a salt thereof by the aforementioned method of converting compound (IV) to compound (VIII) or a method known per se.
- R 1a is an aryl group having substituent(s), or a salt thereof, and a compound represented by the formula
- R 1′ is as defined for the aforementioned R 1 , preferably [1] a phenyl group optionally substituted by 1 to 5 substituents selected from (i) a halogen atom and (ii) C 1-6 alkyl optionally substituted by 1 to 5 halogen atoms, or [2] a pyridyl group optionally substituted by 1 to 4 substituents selected from lower (C 1-6 ) alkyl, a halogen atom, alkoxy (C 1-6 alkoxy), cyano, acyl (e.g., acetyl), nitro and amino, which is a preferable example of R 1 , and further preferably [1] a phenyl group having one substituent selected from (i) a halogen atom and (ii) C 1-6 alkyl optionally substituted by 1 to 5 halogen atoms, at the 2-position, or [2] a pyridyl group optionally substituted 1 to 4 substituents selected from
- 2-position substituted phenyl e.g., 2-fluorophenyl, 2-methylphenyl etc. is particularly preferable.
- the “room temperature” generally means about 10° C. to about 35° C., but it is not particularly strictly limited.
- the mixing ratio of liquids shows a volume ratio.
- “%” means weight %.
- the yield is in mol/mol %.
- Silica gel column chromatography was performed using silica gel 60 (0.063-0.200 mm) manufactured by MERCK or Fuji Silysia Chemical Ltd. Chromatorex (trade name) NH (described as basic silica gel column chromatography). The melting point was measured using Yanagimoto trace melting point measurement apparatus or
- the mixture was continuously stirred at the internal temperature of 20-30° C. for 0.5 hr and at the internal temperature of 0-10° C. for 1 hr.
- the precipitated crystals were collected by filtration, washed with cold ethyl acetate (270 ml), and dried under reduced pressure at 50° C. until a constant weight was reached to give the title compound (73.9 g, yield 50.2%).
- the mixture was continuously stirred at the internal temperature of 55-65° C. for 1 hr and at the internal temperature of 20-30° C. for 1 hr.
- the precipitated crystals were collected by filtration, washed with a cold mixed solution of acetonitrile and water (1:1, 10 ml), and dried under reduced pressure at 50° C. until a constant weight was reached to give the title compound (4.59 g, yield 84.2%).
- N,N-Dimethylacetamide (4 ml), [2-(2-fluorophenyl)-2-oxoethyl]propanedinitrile (500 mg, 2.47 mmol) and triethylamine (5.51 g, 54.41 mmol) were added in a flask, and ice-cooled.
- Formic acid (2.28 g, 49.46 mmol) was added dropwise while paying attention to heat generation. The mixture was warmed to room temperature, and purged with an inert gas. 5% Pd—C (N.E. CHEMCAT, 500 mg) was added, and the mixture was reacted at room temperature for 2.5 hr.
- the mixture was reacted at room temperature for 1 hr, and tap water (87.5 ml) was added to the reaction mixture.
- 0.5 N HCl was added dropwise to adjust to pH 4.5, and the mixture was stirred at room temperature for 1 hr.
- the precipitated crystals were collected by filtration, and washed with a mixture of acetonitrile (21.2 ml) and water (21.2 ml). The wet crystals were dried under reduced pressure at 50° C. to give the title compound (54.8 g, yield 90%).
- the mixture was stirred at the internal temperature of 50-55° C. for 1 hr.
- the suspension was cooled to 20-30° C., and stirred at the same temperature for 1 hr, and further at 0-10° C. for 1 hr.
- the precipitated crystals were collected by filtration, and washed with ethyl acetate (80 ml) The wet crystals were dried under reduced pressure at 50° C. until a constant weight was reached to give the title compound (38 g, yield 85%).
- the aqueous layer was extracted with ethyl acetate (180 ml). The organic layers were combined, washed with about 5% brine (180 ml) and partitioned. The organic layer was concentrated to 40 g, ethyl acetate (300 ml) was added and the mixture was concentrated again. This operation was performed twice, and the mixture was concentrated to the total amount of 165 g. N,N-Dimethylformamide (150 ml) was added to the concentrated residue, and the mixture was heated to the internal temperature of 50-60° C. Fumaric acid (9.6 g, 82.7 mmol) was added. The mixture was stirred at the internal temperature of 50-60° C. for 30 min, allowed to cool and stirred at 20-30° C.
- a crude product (100 g) of N-methyl-1-[5-(2-methylphenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine fumarate and 10% hydrous methanol (900 ml) were added in a four neck flask, and the mixture was dissolved by heating. Insoluble material was filtered off, and washed with 10% hydrous methanol (100 ml). The filtrate was heated again to the refluxing temperature, and stirred for 30 min. After cooling to 40-45° C., the mixture was stirred at the same temperature for 1 hr, at room temperature for 16 hr, and further at 10° C. or below for 1 hr.
- the precipitated crystals were collected by filtration, and washed with cold 50% hydrous methanol (100 ml). The wet crystals were dried under reduced pressure at 50° C. until a constant weight was reached to give the title compound (72 g, yield 72%).
- the precipitated crystals were collected by filtration, washed with a mixture of acetonitrile (11 ml) and water (11 ml). The wet crystals were dried under reduced pressure to give the title compound (25.8 g, yield 80.7%).
- Sulfonylpyrrole compound (VIII) obtained by the method of the present invention is useful as an acid secretion inhibitor (proton pump inhibitor).
- 3-cyanopyrrole compound (III) obtained by the method of the present invention is useful as an intermediate for producing sulfonylpyrrole compound (VIII).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
wherein r1 is a monocyclic nitrogen-containing heterocyclic group optionally condensed with a benzene ring or a heterocycle, wherein the monocyclic nitrogen-containing heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), r2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, r3 and r4 are each a hydrogen atom, or one of r3 and r4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and r3 is an alkyl group, or a salt thereof.
| TABLE 1 | ||||
| wa | xa | ya | za | Rd |
| 3-CN | 4-Cl | 5-Cl | 2-(p-CF3O—C6H5) | C2H5 |
| 4-NO2 | 2-Br | 3-Br | 5-(p-Cl—C6H5) | C2H5 |
| 4-NO2 | 2-Cl | 3-Cl | 5-(3,4-diCl—C6H5) | C2H5 |
| 4-NO2 | 2-Cl | 3-Cl | 5-(p-Br—C6H5) | C2H5 |
| 3-CN | 4-Cl | 5-Cl | 2-(p-CF3—C6H5) | C2H5 |
| 3-CN | 4-Cl | 5-Cl | 2-(3,4-diCl—C6H5) | C2H5 |
| 3-CN | 4-Cl | 5-Cl | 2-(p-Cl—C6H5) | C2H5 |
| 4-NO2 | 2-(p-Cl—C6H5) | 5-CF3 | 2-(p-Cl—C6H5) | C2H5 |
| 3-CN | 4-Br | 5-Br | 2-Br | C2H5 |
| 3-CN | 4-Br | 5-CF3 | 2-(p-Cl—C6H5) | C2H5 |
| 3-CN | 4-Cl | 5-CF3 | 2-(p-Cl—C6H5) | C2H5 |
| 4-NO2 | 3-(p-Cl—C6H5) | 5-CF3 | 2-(p-Cl—C6H5) | C2H5 |
| 3-NO2 | 4-(3,4-diCl—C6H5) | 5-CF3 | 2-(p-Cl—C6H5) | C2H5 |
| 4-NO2 | 3-(m-CN—C6H5) | 2-CF3 | 5-(p-Cl—C6H5) | C2H5 |
| 3-CN | 4-Br | 5-Br | 2-(p-CF3—C6H5) | C2H5 |
| 3-CN | 2-Cl | 4-Cl | 5-(3,4-diCl—C6H5) | C2H5 |
| 3-CN | 2-Cl | 4-Br | 5-(p-Br—C6H5) | C2H5 |
Patent Document 8
| TABLE 2 | ||||||
| Compound No | Qn | xb | yb | zb | ||
| 2-5 | 3-Cl | H | CN | H | ||
| 2-6 | 3-Cl | CH3 | CN | H | ||
| 2-7 | 3-Cl | Cl | CN | H | ||
| 2-8 | 3-Cl | Br | CN | H | ||
| 2-31 | 3-Cl | H | CN | CH3 | ||
| 2-32 | 3-Cl | H | CN | CHO | ||
| 2-57 | 3-Me | H | CN | H | ||
| 2-58 | 3-Me | CH3 | CN | H | ||
| 2-59 | 3-Me | Cl | CN | H | ||
| 2-60 | 3-Me | Br | CN | H | ||
| 2-72 | 3-Me | H | CN | CH3 | ||
| 2-73 | 3-Me | H | CN | CHO | ||
| 2-92 | 3-cyclopropyl | H | CN | H | ||
| 2-93 | 3-cyclopropyl | CH3 | CN | H | ||
| 2-94 | 3-cyclopropyl | Cl | CN | H | ||
| 2-95 | 3-cyclopropyl | Br | CN | H | ||
| 2-108 | 3-cyclopropyl | H | CN | CH3 | ||
| 2-109 | 3-cyclopropyl | H | CN | CHO | ||
| TABLE 3 | ||||||
| Compound No | Qn | xb | yb | zb | ||
| 2-128 | 5-cyclopropyl | H | CN | H | ||
| 2-129 | 5-cyclopropyl | CH3 | CN | H | ||
| 2-130 | 5-cyclopropyl | Cl | CN | H | ||
| 2-131 | 5-cyclopropyl | Br | CN | H | ||
| 2-145 | 5-cyclopropyl | H | CN | CH3 | ||
| 2-146 | 5-cyclopropyl | H | CN | CHO | ||
| 2-157 | 5-Et | H | CN | H | ||
| 2-158 | 5-Et | CH3 | CN | H | ||
| 2-159 | 5-Et | Cl | CN | H | ||
| 2-160 | 5-Et | Br | CN | H | ||
| 2-175 | 5-Et | H | CN | CH3 | ||
| 2-176 | 5-Et | H | CN | CHO | ||
| 2-195 | 3-C≡CH | H | CN | H | ||
| 2-196 | 3-C≡CH | CH3 | CN | H | ||
| 2-197 | 3-C≡CH | Cl | CN | H | ||
| 2-198 | 3-C≡CH | Br | CN | H | ||
| 2-212 | 3-C≡CH | H | CN | CH3 | ||
| 2-213 | 3-C≡CH | H | CN | CHO | ||
non-patent document 6 describes 2-mercaptopyrrole derivative (B) having a cyano group at the 3-position:
patent document 11 describes 2-mercaptopyrrole derivative (C) having a cyano group at the 3-position:
and
patent document 12 describes 2-mercaptopyrrole derivative (D) having a cyano group at the 3-position:
- patent document 1: WO2006/036024
- patent document 2: WO2007/026916
- patent document 3: WO2004/103968
- patent document 4: JP-A-6-9554
- patent document 5: U.S. Pat. No. 4,904,687
- patent document 6: EP-A-358047
- patent document 7: EP-A-491136
- patent document 8: U.S. Pat. No. 5,359,090
- patent document 9: U.S. Pat. No. 5,563,279
- patent document 10: JP-A-10-324687
- patent document 11: WO2005/040110
- patent document 12: WO2006/064944
- non-patent document 1: J. Med. Chem., 1995, 38 (12), 2158-2165
- non-patent document 2: Nucleosides Nucleotides, 1997, 16 (7-9), 941-944
- non-patent document 3: J. Med. Chem., 1995, 38 (20), 4106-4144
- non-patent document 4: Can. J. Chem., 1980, 58, 409-411
- non-patent document 5: Chemistry Heterocyclic Compound, 1992, vol. 2, page 277
- non-patent document 6: Tetrahedron, 1991, vol. 47, page 8243
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, R3 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R4 is an alkyl group, or a salt thereof. As a result, they have found a novel production method of a sulfonylpyrrole compound, which uses a 3-cyanopyrrole compound. In addition, they have found a novel production method of a 3-cyanopyrrole compound, which is an intermediate, and a novel intermediate, which resulted in the completion of the present invention.
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, R3 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R4 is an alkyl group, or a salt thereof, comprising
(I) reducing a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, and hydrolyzing the reduced product to give a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, (II) reacting the obtained compound with a compound represented by the formula
R3—SO2—X (V)
wherein R3 is as defined above and X is a leaving group, or a salt thereof, to give a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, and
(III) reacting the obtained compound with a compound represented by the formula
R4—NH2 (VII)
wherein R4 is as defined above, or a salt thereof, in the presence of a reducing agent;
(2) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising subjecting a compound represented by the formula
wherein X1 is a halogen atom and other symbols are as defined above, or a salt thereof, to dehalogenation;
(3) the production method of the aforementioned (2), wherein the dehalogenation is performed in the presence of a base;
(4) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising reducing a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, and hydrolyzing the reduced product;
(5) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, R5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group or a group represented by —S—R6 (R6 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), and n is 0, 1 or 2, or a salt thereof, comprising reacting a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, with a compound represented by the formula
R5S(O)nH
wherein R5 and n are as defined above, or a salt thereof;
(6) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising subjecting a compound represented by the formula
wherein R1 and R2 are as defined above, R5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group or a group represented by —S—R6 (R6 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), and n is 0, 1 or 2, or a salt thereof, to a desulfurization reaction;
(7) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, R3 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R4 is an alkyl group, or a salt thereof, comprising
(I) reacting a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, with a compound represented by the formula
R5S(O)nH
wherein R5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group or a group represented by —S—R6 (R6 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), and n is 0, 1 or 2, or a salt thereof, to give a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, (II) subjecting the obtained compound to a desulfurization reaction to give a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, (III) reacting the obtained compound with a compound represented by the formula
R3—SO2—X (V)
wherein R3 is as defined above, and X is a leaving group, or a salt thereof, to give a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, (IV) reducing the obtained compound and hydrolyzing the reduced product to give a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, and
(V) reacting the obtained compound with a compound represented by the formula
R4—NH2 (VII)
wherein R4 is as defined above, or a salt thereof;
(8) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising subjecting a compound represented by the formula
wherein m is 0 or 1 and other symbols are as defined above, or a salt thereof, to a desulfurization reaction;
(9) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, or a salt thereof, comprising reacting a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, with a sulfur reagent to give a compound represented by the formula
wherein m is 0 or 1, and other symbols are as defined above, or a salt thereof, and subjecting the obtained compound to a desulfurization reaction;
(10) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R7 is a cyano group or a substituted carboxyl group, and R8 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, a chlorine atom or a fluorine atom, or a salt thereof, comprising subjecting a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, to a reduction reaction;
(11) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R7 is a cyano group or a substituted carboxyl group, and R8 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, a chlorine atom or a fluorine atom, or a salt thereof, comprising cyclizing a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof; (12) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R7 is a cyano group or a substituted carboxyl group, and R8 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, a chlorine atom or a fluorine atom, or a salt thereof, comprising reducing a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, and cyclizing the reduced product;
(13) a method of producing a compound represented by the formula
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R8 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, a chlorine atom or a fluorine atom, or a salt thereof, comprising cyclizing a compound represented by the formula
wherein each symbol is as defined above, or a salt thereof, in the presence of a reducing agent;
(14) a compound represented by the formula
wherein R1a is an aryl group having substituent(s), or a salt thereof;
(15) a compound represented by the formula
wherein R1b is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group or a group represented by —S—R6 (R6 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), and n is 0, 1 or 2 (excluding 2,2′-dithiobis(5-methyl-1H-pyrrole-3-carbonitrile), 2,2′-dithiobis(5-phenyl-1H-pyrrole-3-carbonitrile), 2,2′-dithiobis[5-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile], 2,2′-dithiobis[5-(4-methylphenyl)-1H-pyrrole-3-carbonitrile] and 2,2′-dithiobis[5-(4-methoxyphenyl)-1H-pyrrole-3-carbonitrile]), or a salt thereof.
wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2 is a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a chlorine atom or a fluorine atom, R3 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R4 is an alkyl group (hereinafter sometimes to be abbreviated as compound (VIII)) or a salt thereof, a production method of an intermediate therefor and the like. Compound (VIII) or a salt thereof shows a highly strong proton pump inhibitory effect. Since compound (VIII) or a salt thereof inhibits the proton pump (H+/K+-ATPase) activity reversibly and in a K+ antagonist inhibitory manner to consequently suppress acid secretion, it is sometimes referred to as a potassium-competitive acid blocker: P-CAB or an acid pump antagonist (APA). Compound (VIII) or a salt thereof rapidly expresses action, and shows maximum efficacy from the initial administration. Furthermore, it is characterized by a small influence of metabolism polymorphisms (dispersion among patients), low cytotoxicity, weak cytochrome P450 (CYP) inhibitory activity and hERG inhibitory activity, and long duration of action. Therefore, compound (VIII) or a salt thereof obtained according to the production method of the present invention is useful as an agent clinically useful for the prophylaxis and/or treatment of peptic ulcer (e.g., gastric ulcer, duodenal ulcer, anastomotic ulcer, ulcer caused by non-steroidal anti-inflammatory agents, ulcer due to postoperative stress etc.); Zollinger-Ellison syndrome; gastritis; erosive esophagitis; symptomatic gastroesophageal reflux disease (symptomatic GERD); Barrett esophagus, functional dyspepsia; gastric cancer; stomach MALT lymphoma; gastric hyperacidity; or an inhibitor of upper gastrointestinal hemorrhage due to peptic ulcer, acute stress ulcer, hemorrhagic gastritis or invasive stress or recurrence of ulcer due to non-steroidal anti-inflammatory agents and the like. Since compound (VIII) or a salt thereof shows low toxicity and is superior in water-solubility, in vivo kinetics and efficacy expression, it is useful as a pharmaceutical composition. Moreover, since compound (VIII) or a salt thereof is stable even under acidic conditions, it can be administered orally as a conventional tablet and the like without being formulated as an enteric-coated preparation. This has a consequence that the preparation of tablet and the like can be made smaller, which is advantageous in that it is easily swallowed by patients having difficulty in swallowing, particularly the elderly and children. In addition, since a sustained release effect afforded by enteric-coated preparations is absent, expression of a gastric acid secretion-suppressive action is rapid, and alleviation of symptoms such as pain and the like is rapid.
[3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) lower (specifically C1-6) alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (v) acyl (e.g., acetyl), (vi) nitro and (vii) amino is preferable.
[3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) lower (specifically C1-6) alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (v) acyl (e.g., acetyl), (vi) nitro and (vii) amino is preferable.
[3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) lower (specifically C1-6) alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine) is preferable.
[2] a thienyl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) C1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine) and (v) acetyl,
[3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine), (ii) cyano, (iii) lower (specifically C1-6) alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (iv) C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), (v) acyl (e.g., acetyl), (vi) nitro and (vii) amino, or
[4] a bipyridyl group optionally substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine); R2 is a hydrogen atom, a C1-6 alkyl group (e.g., methyl, ethyl, n-propyl, isobutyl etc.), a C1-6 alkyl-carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl, heptanoyl etc.), a fluorine atom or a chlorine atom, and R4 is methyl or ethyl is preferable,
[3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) lower (specifically C1-6) alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), and R2 is a hydrogen atom, and R4 is methyl.
[4] an optionally substituted C1-7 alkanoyl group (e.g., formyl; C1-6 alkyl-carbonylacetyl such as propionyl, butyryl, isobutyryl, pentanoyl, hexanoyl, heptanoyl and the like, etc.) is preferable.
[2] a thienyl group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) C1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine), or
[3] a pyridyl group optionally substituted by 1 to 4 substituents selected from (i) a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and (ii) lower (specifically C1-6) alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 5 (preferably 1 to 3) halogens (e.g., fluorine, chlorine, bromine, iodine) is preferable.
wherein R1a is an aryl group having substituent(s), or a salt thereof, and a compound represented by the formula
wherein R1b is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group or a group represented by —S—R6 (R6 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), and n is 0, 1 or 2 (excluding 2,2′-dithiobis(5-methyl-1H-pyrrole-3-carbonitrile), 2,2′-dithiobis(5-phenyl-1H-pyrrole-3-carbonitrile), 2,2′-dithiobis[5-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile], 2,2′-dithiobis[5-(4-methylphenyl)-1H-pyrrole-3-carbonitrile] and 2,2′-dithiobis[5-(4-methoxyphenyl)-1H-pyrrole-3-carbonitrile]) or a salt thereof are novel compounds.
wherein each symbol is as defined above, when R5 is —S—R6 (R6 is as defined above), a preferable embodiment of R6 is
wherein R1′ is as defined for the aforementioned R1, preferably [1] a phenyl group optionally substituted by 1 to 5 substituents selected from (i) a halogen atom and (ii) C1-6 alkyl optionally substituted by 1 to 5 halogen atoms, or [2] a pyridyl group optionally substituted by 1 to 4 substituents selected from lower (C1-6) alkyl, a halogen atom, alkoxy (C1-6 alkoxy), cyano, acyl (e.g., acetyl), nitro and amino, which is a preferable example of R1, and further preferably [1] a phenyl group having one substituent selected from (i) a halogen atom and (ii) C1-6 alkyl optionally substituted by 1 to 5 halogen atoms, at the 2-position, or [2] a pyridyl group optionally substituted 1 to 4 substituents selected from lower (C1-6) alkyl, a halogen atom, alkoxy (C1-6 alkoxy), cyano, acyl (e.g., acetyl), nitro and amino, and R2 is as defined above, and
wherein each symbol is as defined above, is a preferable embodiment of the aforementioned R5. Particularly, R5 is
[1] a C1-6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (ii) nitro, (iii) amino and (iv) carboxyl,
[2] a C6-14 aryl group (e.g., phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (ii) nitro, (iii) amino and (iv) carboxyl,
[3] a heterocyclic group (e.g., pyridyl (e.g., 2-, 3- or 4-pyridyl) etc.),
[4] an optionally substituted C6-14 aryl-carbonyl group (e.g., benzoyl, naphthalenecarbonyl etc.), or
[5] a group represented by the formula
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/961,978 US12351553B2 (en) | 2009-02-25 | 2022-10-07 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009042975 | 2009-02-25 | ||
| JP2009-042975 | 2009-02-25 | ||
| PCT/JP2010/052874 WO2010098351A1 (en) | 2009-02-25 | 2010-02-24 | Process for producing pyrrole compound |
| US201113203441A | 2011-08-25 | 2011-08-25 | |
| US14/303,238 US9266831B2 (en) | 2009-02-25 | 2014-06-12 | Process for producing pyrrole compound |
| US14/994,360 US10173977B2 (en) | 2009-02-25 | 2016-01-13 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US16/200,178 US10538489B2 (en) | 2009-02-25 | 2018-11-26 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US16/691,912 US10844011B2 (en) | 2009-02-25 | 2019-11-22 | Process for producing pyrrole compound |
| US17/021,701 US11498898B2 (en) | 2009-02-25 | 2020-09-15 | Process for producing pyrrole compound |
| US17/961,978 US12351553B2 (en) | 2009-02-25 | 2022-10-07 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/021,701 Division US11498898B2 (en) | 2009-02-25 | 2020-09-15 | Process for producing pyrrole compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20230088365A1 US20230088365A1 (en) | 2023-03-23 |
| US12351553B2 true US12351553B2 (en) | 2025-07-08 |
Family
ID=42665557
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/203,441 Active 2030-05-12 US8822694B2 (en) | 2009-02-25 | 2010-02-24 | Process for producing pyrrole compound |
| US14/303,238 Active US9266831B2 (en) | 2009-02-25 | 2014-06-12 | Process for producing pyrrole compound |
| US14/994,360 Active 2030-10-28 US10173977B2 (en) | 2009-02-25 | 2016-01-13 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US16/200,178 Active US10538489B2 (en) | 2009-02-25 | 2018-11-26 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US16/691,912 Active US10844011B2 (en) | 2009-02-25 | 2019-11-22 | Process for producing pyrrole compound |
| US17/021,701 Active 2030-03-21 US11498898B2 (en) | 2009-02-25 | 2020-09-15 | Process for producing pyrrole compound |
| US17/961,978 Active 2030-05-21 US12351553B2 (en) | 2009-02-25 | 2022-10-07 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/203,441 Active 2030-05-12 US8822694B2 (en) | 2009-02-25 | 2010-02-24 | Process for producing pyrrole compound |
| US14/303,238 Active US9266831B2 (en) | 2009-02-25 | 2014-06-12 | Process for producing pyrrole compound |
| US14/994,360 Active 2030-10-28 US10173977B2 (en) | 2009-02-25 | 2016-01-13 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US16/200,178 Active US10538489B2 (en) | 2009-02-25 | 2018-11-26 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US16/691,912 Active US10844011B2 (en) | 2009-02-25 | 2019-11-22 | Process for producing pyrrole compound |
| US17/021,701 Active 2030-03-21 US11498898B2 (en) | 2009-02-25 | 2020-09-15 | Process for producing pyrrole compound |
Country Status (8)
| Country | Link |
|---|---|
| US (7) | US8822694B2 (en) |
| EP (5) | EP3929187A3 (en) |
| JP (2) | JP5628787B2 (en) |
| KR (2) | KR101814357B1 (en) |
| CN (5) | CN105524046B (en) |
| ES (4) | ES2640931T3 (en) |
| MY (3) | MY201120A (en) |
| WO (1) | WO2010098351A1 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2640931T3 (en) | 2009-02-25 | 2017-11-07 | Takeda Pharmaceutical Company Limited | Intermediates for use in a process to produce pyrrole compounds |
| EP2963019B1 (en) | 2013-02-28 | 2020-08-12 | Takeda Pharmaceutical Company Limited | Method for producing pyridine-3-sulfonyl chloride |
| CN103965092B (en) * | 2014-04-24 | 2015-12-02 | 成都安斯利生物医药有限公司 | A kind of bromo-N-of 2-that synthesizes is to the method for Methyl benzenesulfonyl base pyrroles |
| CN104860923B (en) * | 2015-01-21 | 2018-01-12 | 山东康美乐医药科技有限公司 | The preparation method of Vonoprazan fumarate |
| CA2977919A1 (en) * | 2015-02-27 | 2016-09-01 | Op Bio Factory Co., Ltd. | Method for producing kakeromycin and derivatives thereof |
| CN105315258A (en) * | 2015-05-16 | 2016-02-10 | 南京海纳医药科技有限公司 | Vonoprazan fumarate polycrystalline forms and preparation method thereof |
| CN104860926B (en) * | 2015-06-10 | 2017-06-30 | 浙江诚意药业股份有限公司 | A kind of preparation method of Vonoprazan fumarate |
| CN104926790B (en) * | 2015-06-29 | 2017-07-07 | 江苏奥赛康药业股份有限公司 | A kind of high-purity Vonoprazan Fumarate compounds and its intermediate, impurity and their preparation method |
| CA2991115C (en) * | 2015-06-30 | 2024-06-25 | Takeda Pharmaceutical Company Limited | Method for producing pyrrole compound |
| CN106478597A (en) * | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技(武汉)有限公司 | Vonoprazan fumarate monocrystalline and its production and use |
| CN105294653B (en) * | 2015-11-16 | 2017-08-15 | 山东罗欣药业集团股份有限公司 | The preparation technology of Vonoprazan fumarate |
| CN105440019A (en) * | 2015-12-17 | 2016-03-30 | 昆明贵研药业有限公司 | A kind of preparation method of medicine for treating gastric acid disease |
| CN105503828A (en) * | 2015-12-24 | 2016-04-20 | 北京康立生医药技术开发有限公司 | Preparation method of fumarate of pyrrole derivatives |
| CN108191830B (en) * | 2016-06-30 | 2019-06-14 | 珠海赛隆药业股份有限公司(长沙)医药研发中心 | A kind of Vonoprazan fumarate intermediate IV and preparation method thereof |
| CN106187852B (en) * | 2016-07-07 | 2019-01-15 | 江西同和药业股份有限公司 | A kind of preparation method of Vonoprazan fumarate intermediate |
| CN106243008B (en) * | 2016-08-22 | 2018-09-04 | 山东金城生物药业有限公司 | The preparation method of Vonoprazan fumarate intermediate 5- (2- fluorophenyls) -1H- pyrroles's -3- formaldehyde |
| CN107778207A (en) * | 2016-08-25 | 2018-03-09 | 广东东阳光药业有限公司 | Fumaric acid vornorazan intermediate and its preparation method and use |
| CN107793343B (en) * | 2016-09-07 | 2020-08-07 | 广东东阳光药业有限公司 | A kind of preparation method of pyrrole compound |
| CN107162949A (en) * | 2017-07-12 | 2017-09-15 | 北京天弘天达医药科技股份有限公司 | A kind of Vonoprazan fumarate key intermediate and preparation method thereof |
| CN107236127A (en) * | 2017-07-21 | 2017-10-10 | 张娟 | A kind of preparation method of compound monomer denatured conductive material |
| CN107236126A (en) * | 2017-07-21 | 2017-10-10 | 张娟 | A kind of preparation method of high-conductivity composite material |
| US10207974B1 (en) | 2017-12-05 | 2019-02-19 | Chevron Phillips Chemical Company Lp | Synthesis of gamma dicarbonyl and pyrrole compounds |
| CN108503621B (en) * | 2017-12-25 | 2021-09-14 | 上海中拓医药科技有限公司 | Preparation method of vonoprazan fumarate |
| CN111527067B (en) * | 2017-12-27 | 2024-06-25 | 日本化学药品株式会社 | Method for producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethylamine monofumarate |
| CN110396080B (en) * | 2018-04-24 | 2022-07-08 | 广东东阳光药业有限公司 | Vonoprazan fumarate metabolite and preparation method of deutero metabolite thereof |
| US11798126B2 (en) | 2018-07-30 | 2023-10-24 | Hewlett-Packard Development Company, L.P. | Neural network identification of objects in 360-degree images |
| CN110272409A (en) * | 2019-03-11 | 2019-09-24 | 南京百迪尔生物医药有限公司 | The new method of one-step synthesis method Wo Nuolazan |
| CN116987063B (en) * | 2019-09-23 | 2026-02-06 | 吉林汇康制药有限公司 | Preparation method of low-impurity Vonoprazan fumarate |
| CN111018835B (en) * | 2019-12-16 | 2022-09-20 | 株洲千金药业股份有限公司 | Purification method of Vonoprazan |
| CN113511995B (en) * | 2020-04-10 | 2024-07-09 | 四川科伦药物研究院有限公司 | Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| CN112194607A (en) * | 2020-08-27 | 2021-01-08 | 河北科博莱特医药科技有限公司 | Synthetic method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| CN114149411B (en) * | 2020-09-08 | 2025-05-16 | 鲁南制药集团股份有限公司 | A kind of vonoprazan intermediate and its preparation method and application |
| CN114195694A (en) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | A kind of preparation method of pyrrole compound |
| CN112812099B (en) * | 2021-01-19 | 2022-04-26 | 珠海赛隆药业股份有限公司 | Compound for treating peptic ulcer and preparation method and application thereof |
| CN113173876B (en) * | 2021-04-16 | 2022-04-29 | 南京海纳医药科技股份有限公司 | A kind of preparation method of fumaric acid vonorazine intermediate |
| CN113620930B (en) * | 2021-07-12 | 2022-08-16 | 南京烁慧医药科技有限公司 | Compound containing sulfonamide structure, preparation method and application thereof, and pharmaceutical composition and application thereof |
| CN113651746A (en) * | 2021-08-16 | 2021-11-16 | 杭州煌森生物科技有限公司 | Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| CN116143677A (en) * | 2021-09-28 | 2023-05-23 | 北京济美堂医药研究有限公司 | A kind of preparation method of the key intermediate of vonolasan fumarate |
| CN113845459B (en) * | 2021-10-14 | 2023-04-07 | 山东诚创蓝海医药科技有限公司 | Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| CN114539219A (en) * | 2022-03-17 | 2022-05-27 | 日照正济药业有限公司 | Preparation method of Voranolan fumarate |
| CN115232107A (en) * | 2022-07-29 | 2022-10-25 | 南京唯创远医药科技有限公司 | Preparation method of high-purity Voranolan fumarate |
| CN116178239B (en) * | 2022-12-30 | 2024-03-29 | 山东铂源药业股份有限公司 | Synthesis method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| CN116041326A (en) * | 2023-02-20 | 2023-05-02 | 上海北卡医药技术有限公司 | Vonolasan hydrochloride crude product, high-quality product and preparation method of vornosan fumarate |
| CN117736132A (en) * | 2023-12-14 | 2024-03-22 | 杭州煌森生物科技有限公司 | Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| CN117647607B (en) * | 2024-01-30 | 2024-04-26 | 山东百诺医药股份有限公司 | HPLC detection method for simultaneously determining related substances in 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde |
| IT202400004474A1 (en) | 2024-02-29 | 2025-08-29 | Dipharma Francis S R L | METHOD OF PURIFICATION OF A DRUG USED FOR THE TREATMENT OF GASTRIC ACIDITY |
Citations (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0005156A1 (en) | 1978-03-13 | 1979-11-14 | E.I. Du Pont De Nemours And Company | 4,5-diaryl-2-(substituted-thio)-pyrroles and their corresponding sulfoxides and sulfones, process for their preparation and pharmaceutical compositions containing them |
| US4546099A (en) | 1983-07-22 | 1985-10-08 | Ciba-Geigy Corporation | N-Aminomethyl-3-phenyl-4-cyanopyrrole derivatives, compositions and use thereof as microbicides |
| US4904687A (en) | 1987-07-24 | 1990-02-27 | Bayer Aktiengesellschaft | Fungicidal substituted 3-arylpyrroles |
| EP0358047A2 (en) | 1988-09-08 | 1990-03-14 | American Cyanamid Company | Method of controlling phytopathogenic fungi |
| US5010098A (en) | 1987-07-29 | 1991-04-23 | American Cyanamid Company | Arylpyrrole insecticidal acaricidal and nematicidal agents and methods for the preparation thereof |
| US5101042A (en) | 1990-12-11 | 1992-03-31 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
| US5122615A (en) | 1990-12-11 | 1992-06-16 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
| EP0491136A2 (en) | 1990-12-17 | 1992-06-24 | American Cyanamid Company | Process for the manufacture of pesticidal 1-(alkoxymethyl)pyrrole compounds |
| US5252746A (en) | 1990-12-11 | 1993-10-12 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
| US5359090A (en) | 1993-12-29 | 1994-10-25 | American Cyanamid Company | Alkoxymethylation of pyrroles |
| US5480902A (en) | 1993-08-31 | 1996-01-02 | American Cyanamid Company | Thienylpyrrole fungicidal agents |
| US5563279A (en) | 1992-11-30 | 1996-10-08 | American Cyanamid Company | Debrominative chlorination of pyrroles |
| JPH10324687A (en) | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | Pyrrole compound, production and agricultural and horticultural microbicide |
| US6271392B1 (en) | 1994-10-07 | 2001-08-07 | Rhone-Poulenc Inc. | Intermediates useful for the synthesis of 1-arylpyrrole pesticides |
| WO2002030358A2 (en) | 2000-10-11 | 2002-04-18 | Tularik Inc. | Modulation of ccr4 function |
| US20040053931A1 (en) | 2001-06-21 | 2004-03-18 | Cox Paul J. | Azaindoles |
| WO2004103968A1 (en) | 2003-05-26 | 2004-12-02 | Aponetics Ag | Sulfopyrroles |
| WO2005040110A1 (en) | 2003-10-08 | 2005-05-06 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| WO2006036024A1 (en) | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| WO2006064944A1 (en) | 2004-12-14 | 2006-06-22 | Takeda Pharmaceutical Company Limited | Substituted pyrrole derivative |
| WO2007026916A1 (en) | 2005-08-30 | 2007-03-08 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
| WO2007110344A1 (en) | 2006-03-27 | 2007-10-04 | Nerviano Medical Sciences S.R.L. | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
| US20080090882A1 (en) | 2004-10-21 | 2008-04-17 | Merck Patent Gmbh | Heterocyclic Carbonyl Compounds |
| WO2008108380A2 (en) | 2007-02-28 | 2008-09-12 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| US8822694B2 (en) | 2009-02-25 | 2014-09-02 | Takeda Pharmaceutical Company Limited | Process for producing pyrrole compound |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1026206C (en) * | 1987-07-29 | 1994-10-19 | 美国氰胺公司 | Arylpyrrole insecticidal acaricidal and nematicidal agents and method for preparation thereof |
| JP4888275B2 (en) | 2007-08-08 | 2012-02-29 | 三菱電機株式会社 | Intrusion detection device |
-
2010
- 2010-02-24 ES ES14152159.1T patent/ES2640931T3/en active Active
- 2010-02-24 MY MYPI2019001759A patent/MY201120A/en unknown
- 2010-02-24 ES ES17174350T patent/ES2770027T3/en active Active
- 2010-02-24 CN CN201610008203.4A patent/CN105524046B/en active Active
- 2010-02-24 EP EP21187758.4A patent/EP3929187A3/en active Pending
- 2010-02-24 EP EP10746231.9A patent/EP2402313B1/en active Active
- 2010-02-24 MY MYPI2024000404A patent/MY210229A/en unknown
- 2010-02-24 KR KR1020177008990A patent/KR101814357B1/en active Active
- 2010-02-24 ES ES19199941T patent/ES2898438T3/en active Active
- 2010-02-24 EP EP19199941.6A patent/EP3613734B1/en active Active
- 2010-02-24 JP JP2011501618A patent/JP5628787B2/en active Active
- 2010-02-24 CN CN201410373855.9A patent/CN104211618B/en active Active
- 2010-02-24 MY MYPI2011004012A patent/MY173940A/en unknown
- 2010-02-24 CN CN201810122685.5A patent/CN108129374A/en active Pending
- 2010-02-24 CN CN201080018114.9A patent/CN102421753B/en active Active
- 2010-02-24 CN CN202210454794.3A patent/CN114835619A/en active Pending
- 2010-02-24 WO PCT/JP2010/052874 patent/WO2010098351A1/en not_active Ceased
- 2010-02-24 EP EP17174350.3A patent/EP3241826B1/en active Active
- 2010-02-24 ES ES10746231.9T patent/ES2609980T3/en active Active
- 2010-02-24 US US13/203,441 patent/US8822694B2/en active Active
- 2010-02-24 KR KR1020117022156A patent/KR101724293B1/en active Active
- 2010-02-24 EP EP14152159.1A patent/EP2765130B1/en active Active
-
2014
- 2014-06-12 US US14/303,238 patent/US9266831B2/en active Active
- 2014-08-13 JP JP2014165030A patent/JP5819494B2/en active Active
-
2016
- 2016-01-13 US US14/994,360 patent/US10173977B2/en active Active
-
2018
- 2018-11-26 US US16/200,178 patent/US10538489B2/en active Active
-
2019
- 2019-11-22 US US16/691,912 patent/US10844011B2/en active Active
-
2020
- 2020-09-15 US US17/021,701 patent/US11498898B2/en active Active
-
2022
- 2022-10-07 US US17/961,978 patent/US12351553B2/en active Active
Patent Citations (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0005156A1 (en) | 1978-03-13 | 1979-11-14 | E.I. Du Pont De Nemours And Company | 4,5-diaryl-2-(substituted-thio)-pyrroles and their corresponding sulfoxides and sulfones, process for their preparation and pharmaceutical compositions containing them |
| US4546099A (en) | 1983-07-22 | 1985-10-08 | Ciba-Geigy Corporation | N-Aminomethyl-3-phenyl-4-cyanopyrrole derivatives, compositions and use thereof as microbicides |
| US4904687A (en) | 1987-07-24 | 1990-02-27 | Bayer Aktiengesellschaft | Fungicidal substituted 3-arylpyrroles |
| US5010098A (en) | 1987-07-29 | 1991-04-23 | American Cyanamid Company | Arylpyrrole insecticidal acaricidal and nematicidal agents and methods for the preparation thereof |
| EP0358047A2 (en) | 1988-09-08 | 1990-03-14 | American Cyanamid Company | Method of controlling phytopathogenic fungi |
| JPH02167203A (en) | 1988-09-08 | 1990-06-27 | American Cyanamid Co | Method of preventing fungus and bacteria causative |
| US5252746A (en) | 1990-12-11 | 1993-10-12 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
| US5101042A (en) | 1990-12-11 | 1992-03-31 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
| US5122615A (en) | 1990-12-11 | 1992-06-16 | American Cyanamid Company | Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds |
| EP0491136A2 (en) | 1990-12-17 | 1992-06-24 | American Cyanamid Company | Process for the manufacture of pesticidal 1-(alkoxymethyl)pyrrole compounds |
| US5563279A (en) | 1992-11-30 | 1996-10-08 | American Cyanamid Company | Debrominative chlorination of pyrroles |
| US5480902A (en) | 1993-08-31 | 1996-01-02 | American Cyanamid Company | Thienylpyrrole fungicidal agents |
| US5359090A (en) | 1993-12-29 | 1994-10-25 | American Cyanamid Company | Alkoxymethylation of pyrroles |
| US6271392B1 (en) | 1994-10-07 | 2001-08-07 | Rhone-Poulenc Inc. | Intermediates useful for the synthesis of 1-arylpyrrole pesticides |
| JPH10324687A (en) | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | Pyrrole compound, production and agricultural and horticultural microbicide |
| WO2002030358A2 (en) | 2000-10-11 | 2002-04-18 | Tularik Inc. | Modulation of ccr4 function |
| US20040053931A1 (en) | 2001-06-21 | 2004-03-18 | Cox Paul J. | Azaindoles |
| CN1665809A (en) | 2001-06-21 | 2005-09-07 | 艾文蒂斯药品有限公司 | Azaindoles |
| WO2004103968A1 (en) | 2003-05-26 | 2004-12-02 | Aponetics Ag | Sulfopyrroles |
| WO2005040110A1 (en) | 2003-10-08 | 2005-05-06 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| WO2006036024A1 (en) | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| US20080139639A1 (en) | 2004-09-30 | 2008-06-12 | Takeda Pharmaceutical Company Limited | Proton Pump Inhibitors |
| US20110028476A1 (en) | 2004-09-30 | 2011-02-03 | Masahiro Kajino | Proton pump inhibitors |
| US20080090882A1 (en) | 2004-10-21 | 2008-04-17 | Merck Patent Gmbh | Heterocyclic Carbonyl Compounds |
| WO2006064944A1 (en) | 2004-12-14 | 2006-06-22 | Takeda Pharmaceutical Company Limited | Substituted pyrrole derivative |
| WO2007026916A1 (en) | 2005-08-30 | 2007-03-08 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
| US7498337B2 (en) | 2005-08-30 | 2009-03-03 | Takeda Pharmaceutical Company Limited | Acid secretion inhibitor |
| WO2007110344A1 (en) | 2006-03-27 | 2007-10-04 | Nerviano Medical Sciences S.R.L. | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
| WO2008108380A3 (en) | 2007-02-28 | 2009-04-16 | Takeda Pharmaceutical | Pyrrole compounds |
| WO2008108380A2 (en) | 2007-02-28 | 2008-09-12 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| US8822694B2 (en) | 2009-02-25 | 2014-09-02 | Takeda Pharmaceutical Company Limited | Process for producing pyrrole compound |
| US9266831B2 (en) | 2009-02-25 | 2016-02-23 | Takeda Pharmaceutical Company Limited | Process for producing pyrrole compound |
| US10173977B2 (en) | 2009-02-25 | 2019-01-08 | Takeda Pharmaceutical Company Limited | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US10538489B2 (en) | 2009-02-25 | 2020-01-21 | Takeda Pharmaceutical Company Limited | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same |
| US10844011B2 (en) | 2009-02-25 | 2020-11-24 | Takeda Pharmaceutical Company Limited | Process for producing pyrrole compound |
| US11498898B2 (en) | 2009-02-25 | 2022-11-15 | Takeda Pharmaceutical Company Limited | Process for producing pyrrole compound |
Non-Patent Citations (22)
| Title |
|---|
| Alonso et al. (Chem. Rev. 2002, 102, 4009-4091). * |
| Balow et al., Positioning of Functionalities in a Heteroduplex Major Groove: Synthesis of 7-Deaza-2-Amino-2'-deoxyadenosines. Nucleosides and Nucleotides. 1997;16(7-9):941-944. |
| Barnett et al., Pyrrole chemistry. XXI. Synthetic approaches to cyanopyrroles. Can J Chem. 1980;58:409-411. |
| Chung et al. (J. Org. Chem. 1980, 45, 4056-4057). * |
| Collins et al., Novel pyrrole-containing progesterone receptor modulators. Bioorg Med Chem Lett. May 3, 2004;14 (9):2185-9. |
| Demir et al., New approaches to polysubstituted pyrroles and pyrrolinones from a-cyanomethyl-beta-ketoesters. Tetrahedron. Jan. 8, 2007;63(2):461-468. |
| Dorwald, Palladium-catalyzed C—C Bond Formation. Side Reactions in Organic Synthesis. A Guide to Successful Synthesis Design. Wiley-VCH Verlag GmbH & KgaA. Chapter 8, pp. 279-308, (2005). |
| Erdmann et al., Synthesis of Pyrroles, a Diazepindione and Substituted 3-Aminoacrylonitriles by Reaction of Bisalkylthioacrylonitriles with alpha-AMinoacid Derivatives. Journal f prakt Chemie. 1988;330(6):1015-1021. |
| European Office Action for Application No. 14152159-1, dated Jul. 9, 2014, 9 pages. |
| European Office Action for Application No. 19199941.6, dated Nov. 19, 2019, 12 pages. |
| Gangjee et al., Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases. J Med Chem. Jun. 9, 1995;38(12):2158-65. |
| International Search Reporting and Written Opinion for Application No. PCT/JP2010/052874, dated Mar. 30, 2010, 24 pages. |
| Khalifa et al., Benzoin in heterocyclic synthesis: Synthesis and reactions of 4-cyano-2,3-diphenyl-2h-pyrrol-5-thione. Tetrahedron. Sep. 16, 1991; 47(38):8243-8250. |
| Krawczyk et al., Synthesis and antiproliferative and antiviral activity of 2'-deoxy-2'-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin. J Med Chem. Sep. 29, 1995;38(20):4106-14. |
| Magnus et al., Synthesis of helical poly-beta-pyrroles. Multiple atropisomerism resulting in helical enantiomorphic conformations. J Am Chem Soc. 1990;112(6):2465-2468. |
| Moiseeva et al., Synthesis of bis(3-cyano-2-pyrrolyl) disulfides. Chemistry of Heterocyclic Compound. 1992;28:232. |
| Morokuma et al., Organic Synthesis III, Aldehyde/Ketone/Quinone. Jikken Kagaku Koza, Courses in Experimental Chemistry, 4th Edition, vol. 21, pp. 90-92, Feb. 5, 1991, edited by the Chemical Society of Japan, Maruzen Co. Ltd. |
| Murineddu et al., Synthesis and cytotoxic activities of pyrrole[2,3-d]pyridazin-4-one derivatives. Chem Pharm Bull (Tokyo). Jun. 2002;50(6):754-9. |
| Nasakin et al., Reactivity of beta, beta-y,7-tetracyanoalkanones, beta, beta-dicyanoalkanones, and 5-amino-4-cyano-2,3-dihydrofurans. Russian Journal of General Chemistry. Jan. 1999;69(2):291-300. |
| Pinna et al., Synthesis and dopamine D2-like receptor binding affinity of substituted 5-phenyl-pyrrole-3-carboxamides. Farmaco. Aug. 30, 1999;54(8):542-50. |
| Smith et al. (Org. Biomol. Chem., 2006, 4, 2477-2482. * |
| Tverdokhlebov et al., A Novel Approach to Pyrrolo[2,1-b][1,3]benzothiazines. Synthesis. 2008;17:2701-2706. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12351553B2 (en) | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | |
| EP1803709B1 (en) | Proton pump inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| AS | Assignment |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IKEMOTO, TOMOMI;MIZUFUNE, HIDEYA;NAGATA, TOSHIAKI;AND OTHERS;REEL/FRAME:061374/0051 Effective date: 20110720 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |






























































































